摘要
24只自发性高血压大鼠(SHR)随机分组,12只给予罗格列酮,12只为空白对照组。采用尾动脉血压间接测定法。用原位杂交和免疫组化检测AT1受体和mRNA表达,观察8周。罗格列酮组SHR大鼠血压明显降低,AT1受体和mRNA表达水平受到抑制。罗格列酮可能通过抑制AT1表达发挥降压和靶器官保护作用。
To evaluate the effect of rosiglitazone on the Angiotensin Ⅱ receptor 1 （AT1） and explore its mechanisms of lowering the blood pressure and protecting the organs, The 24（SHR）rats were divided into 2 groups： 12 were given rosiglitazone, 12 were in the control gronp without any treatment. The duration of observation was 8 weeks. The tail blood pressure was measured indirectly. The in situ hybridization and the immunohistochemical methods were used to estimate the expression of the AT1 mRNA and AT1 receptors of heart. In rosiglitazone group, the blood pressure was reduced significantly,and the expressions of AT1 mRNA and AT1 receptor of heart were inhibited. The effect of rosiglitazone on the expressions of AT1 mRNA and AT1 receptor might be one of the reasons why insulin sensilizers reduce the blood pressure and prevent the organ injuries of hypertension.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2008年第2期119-120,共2页
Chinese Journal of Diabetes
基金
吉林省科技厅课题资助项目(20010517)
